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ABSTRACT: Two Pd-catalyzed methods to access 6‑hetero-
aryl 2-aminopurine ribonucleosides from 6-chloroguanosine
are described. First, Pd-132-catalyzed Suzuki−Miyaura cross-
coupling using a series of boron substrates and 6‑chlorogua-
nosine forms 6-heteroaryl-2-aminopurines in a single step. The
versatility of 6-chloroguanosine is further demonstrated using a
modiﬁed Sonogashira coupling employing potassium iodide as
an additive. Finally, the utility of the 6‑alkynyl-2-aminopurine
ribonucleoside as a dipolarophile in [3 + 2] cycloadditions is
presented, aﬀording triazoles and isoxazoles when reacted with azide and isonitrile 1,3-dipoles, respectively.
Nucleoside analogues are essential molecules for bothclinical and basic research. To date, there are over 30
nucleoside analogues approved for use as antiviral or cytotoxic
agents, with almost 50% of these analogues containing
modiﬁcations to the natural pyrimidine/purine base.1 Addi-
tionally, base-modiﬁed ribonucleosides oﬀer considerable
opportunities to enhance the eﬃcacy and cellular uptake
properties of therapeutic oligoribonucleotides.2,3 Apart from
clinical applications, base-derivatized nucleoside analogues are
important biotechnological tools for probing fundamental DNA
and RNA biology4−6 and for synthetic biology applications.7−12
Consequently, there is a pressing need for the development of
cost-eﬀective synthetic routes that facilitate access to novel
nucleoside building blocks.
The 6-position of purines is a prime modiﬁcation site for
many of these applications.13 Current methods have predom-
inantly focused on C6-arylation of adenosine ribo- and
deoxyribonucleosides.14−24 In contrast, eﬃcient access to C6-
heteroaryl guanosines,25,26 especially protocols that utilize a
cost-eﬀective coupling partner, such as 1, are notably limited
(Scheme 1).25−29 One key structural diﬀerence between
adenosine and guanosine nucleobases that has the potential
to have a signiﬁcant impact on the success of Pd-catalyzed
cross-couplings is the presence of the N2 exocyclic amine.
Heterocycles containing exocyclic amines are traditionally
challenging substrates for Suzuki−Miyaura cross-couplings,
resulting in variable product yields and the need for the
development of bespoke reaction conditions.30
Thus, a challenge in the nucleoside synthetic arena is to
develop a general set of conditions to prepare 6-heteroaryl
guanosines from cost-eﬀective substrates, such as 1. Previous
mechanistic studies of Suzuki−Miyaura couplings with
heteroaryl chlorides have shown that oxidative addition across
Het−Cl bonds can result in the formation of nonproductive
and catalytically inactive [Pd−Cl] intermediates.30 To
circumvent this problem, current strategies that have been
developed for the preparation of 6-heteroaryl guanosines
require the use of the expensive 6-iodo-2-aminoguanosine (2)
substrate,26,28,31 prepared from 1 via Finkelstein reaction.32
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Cross-coupling strategies such as Stille,33−35 Negishi,36−38 and
other bespoke variants39,40 of these have been explored using
both 1 and 2. However, the toxicity associated with organotin
reagents and the presence of a number of Lewis basic sites and
electrophilic O-protecting groups have limited their broader
utility.
Herein, we show that 1 can be used as a general coupling
partner for the preparation of C6-heteroarylated guanosine
analogues (3) via, for example, a Pd-132-catalyzed Suzuki−
Miyaura cross-coupling methodology (Scheme 1). Further-
more, we demonstrate the utility of 1 as a substrate for
Sonogashira cross-couplings.14,18,41−43 Finally, we showcase the
general utility of alkyne 4 as a dipolarophile in [3 + 2]
cycloadditions with azide and isonitrile 1,3-dipoles to prepare
6‑heteroaryl guanosines (5) comprising 1,4-triazole and
isoxazole units, respectively.
To establish optimal Suzuki−Miyaura coupling conditions,
we used 1 and the boronic acid 6a as our exemplar reagent set.
Exploration of reaction conditions recently developed for
Suzuki−Miyaura cross-couplings with nucleoside heteroaryl
organoborons and aryl iodides aﬀorded product 7a in 58% yield
(entry 1, Table 1).44 Altering the solvent had a minimal impact
on the yield of 7a using catalytic Pd(dppf)Cl2 and K2CO3 as
the base (entries 2 and 3, Table 1), whereas changing the Pd
catalyst to Pd-13245,46 resulted in a marked increase in the yield
of 7a (85%, entry 4, Table 1). After an extensive survey of base
and solvent (entries 4−15, Table 1, Figure S1), the optimal set
of conditions identiﬁed for this reaction were catalytic Pd-132
(10 mol %) and K2CO3 in 1,4-dioxane (90% isolated yield of
7a, entry 6, Table 1).
The utility of 1 as a general substrate for Suzuki−Miyaura
couplings was then explored using a series of boronic acids and
Bpin esters (6a−l, Scheme 2). Each of the sp2−sp2 couplings
aﬀorded the desired products 7a−g,i−k in 57−97% yield,
which surveyed a range of electron-rich and electron-poor aryl
and heteroaryl boron species. Unfortunately, sp3−sp2 couplings
employing substrates 6h,l resulted in the recovery of starting
material from the crude mixture. The addition of Ag2O to the
reaction with 6l again resulted in no reaction and no
consumption of 1.47 Acetyl deprotection of 7a−g,i−k using
K2CO3/MeOH aﬀorded the corresponding free nucleosides
8a−g,i−k. To expand the diversity of heteroaryl substituents
available for installation at the 6-position, we explored the
utility of 1 in Sonogashira cross-couplings with TIPS-acetylene
(9a, Figure 1).
A well-established phenomenon is that the Sonogashira
reaction generally functions best when a (hetero)aryl iodide is
used as a coupling partner.48 Indeed, coupling of acetyl-
protected 6-iodoguanosine (2) with 9a using catalytic
Pd(PPh3)Cl2/CuI produced 10a in 93% yield (Scheme S1).
49
Under similar conditions, only 36% yield of 10a was obtained
when 1 was used as the corresponding substrate (entry 1,
Figure 1a). When Pd(PPh3)Cl2 was replaced with Pd-132
(i.e., 5% Pd-132), the yield of 10a dropped to 21% (Figure S2).
We surmised that the addition of an iodide source to the
reaction mixture would circumvent the need to prepare 2.48,50
A variety of iodide salts were evaluated using a benchmark set
of conditions [i.e., 5 mol % of Pd(PPh3)Cl2, 10 mol % of CuI,
DIPEA, DMF; Figure 1a and Figure S2]. The addition of 1
equiv of alkali metal iodides (i.e., NaI, KI, CsI) resulted in a
signiﬁcant increase in the yield of 10a; going from 36% (i.e., no
iodide additive, entry 1) to 76 (NaI), 86 (KI), and 79% (CsI)
Table 1. Optimization of Suzuki−Miyaura Coupling
entry solvent base Pd catalyst yielda (%)
1 DMF K2CO3 Pd(dppf)Cl2 58
2 DMSO K2CO3 Pd(dppf)Cl2 64
3 1,4-dioxane K2CO3 Pd(dppf)Cl2 54
4 DMF K2CO3 Pd-132 85
5 DMSO K2CO3 Pd-132 69
6 1,4-dioxane K2CO3 Pd-132 90
7 DMF KOAc Pd-132 80
8 DMSO KOAc Pd-132 81
9 1,4-dioxane KOAc Pd-132 80
10 DMF K3PO4 Pd-132 51
11 DMSO K3PO4 Pd-132 66
12 1,4-dioxane K3PO4 Pd-132 50
13 DMF KF on alumina Pd-132 59
14 DMSO KF on alumina Pd-132 73
15 1,4-dioxane KF on alumina Pd-132 67
aIsolated yields.
Scheme 2. Scope of the Suzuki−Miyaura Cross-Coupling
Using 1
aIsolated yields. b92% yield on 1 mmol scale.
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(entries 3, 4, and 7, Figure 1a). Decreasing the equivalents of
KI to substoichiometric quantities resulted in a drop in the
yield of 10a, which is indicative of the need for a stoichiometric
iodide source (entries 4−6, Figure 1a; Figure S2). This was
further conﬁrmed when KCl replaced KI, producing 10a in
only 27% yield (entry 13, Figure 1a). These optimized
conditions were then shown to be compatible with aromatic
(9b) and aliphatic (9c) alkynes, producing 10b and 10c (Figure
1b).
We ﬁnally sought to explore the utility of alkyne 4 as a
dipolarophile in [3 + 2] cycloaddition reactions. TIPS
deprotection of 10a using polymer-supported ﬂuoride
produced 4 in 78% yield (see Supporting Information).
Using 4, a suite of isoxazole and triazole-substituted analogues
12a−e/15a−c were prepared. Both alkyl and aromatic oximes
were tolerated, producing isoxazoles 12a−e in 28−67% yield.
Azides 14a−c formed 1,4-triazoles 15a−c in 21−83% yield
under CuAAC conditions. Due to the nitrogen-rich and polar
scaﬀold of these triazoles, the puriﬁcation of these compounds
required RP-HPLC. Finally, deprotection of the isoxazole and
triazole series with K2CO3/MeOH aﬀorded 13a−e and 16a−c,
respectively (Scheme 3).
In summary, we have developed modular, step-eﬃcient
methodologies for rapid access to a suite of 18 C6-heteroaryl-
functionalized 2-aminopurine nucleosides from the cost-
eﬀective 6-chloroguanosine precursor. Pd-132-catalyzed Suzu-
ki−Miyaura coupling provides aryl and heteroaryl nucleosides
in two steps from 1, whereas ﬁve-membered heteroaryl variants
were prepared in four steps via a single alkyne intermediate
10a. We envisage that the utility of our synthetic approach will
expand the development of guanosine-based analogues for
therapeutic or synthetic biology applications.
Figure 1. (a) Optimization of Sonogashira cross-coupling. (b)
Substrate scope of Sonogashira cross-coupling of 1 using optimized
conditions (entry 4). aIsolated yields. bCompound 10a obtained in
80% yield when conducted on a 1 mmol scale.
Scheme 3. Modular Formation of Isoxazole and Triazole Nucleosides from 4
aIsolated yields. b55% yield on a 1 mmol scale.
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